Bevala-zons to treat non-small cell lung cancer with simultaneous brain metastasis

BackgroundBevacizumab,BEV) is a targeted drug for vascular epidermal growth factor A (VEGF-A)Clinical studies have shown that BEV can improve the progression-free survival of glioblastoma patients, and the FDA has approved BEV for the treatment of glioblastomaBEV can reduce vascular permeability and improve tumor-peripheral edema, thereby reducing symptoms in patients with brain tumorsA meta-analysis showed that of the 57 clinical studies against VEGF-A for brain tumors, 76 percent explicitly excluded patients with brain metastasis, and only four were used for the treatment of brain metastasisTherefore, the efficacy and safety of BEV treatment of brain metastatic tumors are not yet clearMustafa SAscha, center for clinical research at Case Western Reserve University School of Medicine in Ohio, USA, and others used database searches to analyze the efficacy and safety of BEV treatment of brain metastatic tumorsThe results were published online in Scientific Reports in November 2019the results of the study
the study was screened through the Medicare Medicare Reimbursement Database for the treatment of non-small cell lung cancer (non-small cell lung cancer, NSCLC), including first-time patients with brain metastasis and anencephaly; The Parky, and End-Results, SEER database obtains data on clinical and demographic characteristics, chemotherapy regimens, and survival status in patients diagnosed with NSCLC with synchrotron brain metendas from 2010 to 2012Statistical analysis found that 81 patients with NSCLC accompanied simultaneous brain metastasis received BEV treatment and 4343 cases of unused BEV666 patients with No Synchrotron Brain Metastasis were treated with BEV and 35,197 were unused BEVThe survival analysis after adjusting clinical and demographic characteristics showed that BEV treatment was associated with the improvement of survival in patients with NSCLC conjugation of brain metastasis (HR ?0.75; 95% CI, 0.59-0.96; p-0.020); This conclusion is true after the tendency score matchanother study suggests that in 22,258 NSCLC patients in the Flatiron database in the United States, there was no significant difference in survival rates between BEV patients and those treated with overall NSCLC, and the conclusions were similar to those of Mustafa SAscha, among othersconclusions authors believe that the authors' study sample size is large, but the bias of population selection and data integrity do not reflect the true situation of the entire U.S population;